1 of 1
Story summary
- The Trump administration proposed the Global Benchmark for Efficient Drug Pricing (GLOBE) model to reduce Medicare Part B drug costs and align U.S. prices with those in comparable countries, with a start date of October 1, 2026 and a five-year run if approved.
- CMS Administrator Dr. Mehmet Oz emphasized that the model would lower costs while maintaining care quality.
- Experts noted potential financial benefits for seniors but raised concerns about the impact on drug innovation if prices are excessively reduced.
- Final Congressional approval is still pending.
